This statistic displays the prevalence of limiting long-standing illnesses among those older than 55 years of age in England in 2018/19, by gender and age. In this period, chronic illnesses were more prevalent in women in almost all groups compared to men.

Snapshot img

Chronic Disease Management Market Size 2025-2029

The chronic disease management market size is forecast to increase by USD 5.66 billion at a CAGR of 11.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of chronic diseases and an aging population in need of effective care solutions. Technological advancements, such as blockchain, mobile apps, artificial intelligence, and smart pills, are catalysts driving innovation in digital health. These technologies enable remote patient monitoring, telehealth, and data security, making healthcare more accessible and convenient for patients. Tobacco use and related diseases continue to be major challenges, while medical tourism and health insurance are key factors influencing market growth. The use of virtual reality, smartphones, tablets, and software in chronic disease management is transforming healthcare services, offering new opportunities for improvement. However, concerns over medical data privacy and security remain a significant challenge that must be addressed to ensure patient trust and compliance. Overall, the market is poised for continued growth as it adapts to the evolving needs of patients and the healthcare industry.

What will be the Size of the Chronic Disease Management Market During the Forecast Period?

Request Free Sample

The market encompasses a range of healthcare services and digital technologies designed to improve the quality of life for patients suffering from chronic conditions. This market caters to a vast patient population, including those afflicted by heart disease, hypertension, chronic respiratory diseases such as asthma, stroke, tobacco use, physical inactivity, unhealthy diet, and obesity. Healthcare professionals play a pivotal role in managing these conditions through various medical services, therapies, screenings, check-ups, and monitoring. Digital technologies, including telehealth services and mobile apps, have emerged as crucial components of chronic disease management. Telehealth industry solutions enable remote monitoring, care coordination, and consultation, while mobile apps facilitate self-management and patient engagement.
These advancements aim to enhance accessibility, efficiency, and affordability in managing chronic diseases. The market continues to expand, driven by the growing burden of chronic conditions and the increasing adoption of digital health solutions. The integration of digital technologies in healthcare services is expected to further fuel market growth, as healthcare providers seek to optimize care delivery and improve patient outcomes.

How is this Chronic Disease Management Industry segmented and which is the largest segment?

The chronic disease management industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Solutions
  Services


End-user

  Healthcare providers
  Healthcare payers


Disease Type

  Cardiovascular diseases
  Diabetes
  Chronic obstructive pulmonary disorders
  Arthritis
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Type Insights

The solutions segment is estimated to witness significant growth during the forecast period.

The market encompasses digital technologies, telehealth services, and healthcare professionals in addressing the needs of patients suffering from cardiovascular diseases, cancer, diabetes, musculoskeletal disorders, and other chronic conditions. The market's growth is driven by the increasing geriatric population, rising prevalence of chronic diseases, and the demand for improved quality of life. Healthcare services, including consulting services, ambulatory care centers, hospitals, and nursing homes, are integrating digital solutions to enhance care delivery. Telehealth industry solutions, such as mobile apps, smartphones, tablets, and wearable patient devices, facilitate diagnosis, treatment, monitoring, and screenings. Firms are investing in software systems and therapies to address biomarkers related to chronic conditions, such as heart disease, hypertension, asthma, stroke, tobacco use, physical inactivity, unhealthy diet, obesity, hyperglycemia, hyperlipidemia, and elevated blood pressure. Opportunities lie in the development of advanced treatment options and the expansion of medical services in developing regions.

Get a glance at the Chronic Disease Management Industry report of share of various segments Request Free Sample

The solutions segment was valued at USD 3.68 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to

Dataset population: Persons

General health

General health is a self-assessment of a person's general state of health. People were asked to assess whether their health was very good, good, fair, bad or very bad.

For Northern Ireland, 'General health' refers to a person's health over the 12 months prior to Census day (27 March 2011).

Long-term health problem or disability

A long-term health problem or disability that limits a person's day-to-day activities and has lasted or is expected to last at least 12 months. This includes problems that are related to old age.

People were asked to assess whether their daily activities were limited a lot or a little by such a health problem, or whether their daily activities were not limited at all.

Type of long-term condition

People with more than one condition are counted separately for each condition but only once in the 'All people'/'All people in households' and 'One or more conditions' categories.

1. A communication difficulty means a difficulty with speaking or making yourself understood.
2. A mobility or dexterity difficulty means a condition that substantially limits one or more basic physical activities such as walking, climbing stairs, lifting or carrying.
3. An emotional, psychological or mental health condition includes conditions such as depression or schizophrenia.
4. Shortness of breath or difficulty breathing includes conditions such as asthma.
5. A chronic illness includes illnesses such as cancer, HIV, diabetes, heart disease or epilepsy.

A long-term condition refers to a condition which has lasted, or is expected to last, at least 12 months.

This statistic describes the percent distribution of disability-adjusted life-years in the United Kingdom among persons aged under 70 as of 2012, by condition and disease. Cardiovascular diseases contributed to 10.2 of all DALYs among those under 70 years of age. People with mental health problems have been found to have higher rates of physical illnesses than the general population. Mental health can cost up to 13 billion pounds per year and is listed as one of the most common reasons to claim disability benefits in Britain.

Disability-adjusted life-years

Mental health disorders and cancers are among the highest in terms of disability-adjusted life-years (DALYs) in the United Kingdom as of 2012 leading to 20.6 DALYs and 16.9 DALYs, respectively. DALYs are calculated by combining the years of life lost due to premature mortality and the years lost due to disability caused by the condition. In high-income countries, chronic diseases contribute to high DALY values. For example, cardiovascular diseases are among the leading causes of death worldwide at 17.3 million deaths in 2012. Chronic diseases can create indirect costs that can be a major hindrance in low-income families. Reduced income from loss of productivity, forgoing earnings from those that must care for the patient, and potential lost opportunity in young family members who leave school to care for the ill or to help household economy are indirect costs that chronic diseases can incur.

Neuropsychiatric conditions account for almost 15 percent of the global disease burden. However, this value is suspected to be much higher due to the complex relationships between physical and mental illness. It is also quite common for those with mental health disorders to be experiencing more than one disorder. People living in Alabama and California have some of the highest levels of poor mental health in the country, at 40.1 percent and 39.1 percent of the population reporting this condition, respectively, as of 2012. In the United States, 4.4 percent of individuals between 55 and 64 years of age have reported experiencing serious psychological distress.

Forecast: Hospital Average Length of Stay for Chronic Diseases of Tonsils and Adenoids in the UK 2024 - 2028 Discover more data with ReportLinker!

From the financial year 2023 to 2024, approximately 42 percent of working age adults with a disability had a mobility impairment, this share increased to 69 percent in adults who were at the state pension age. This statistic displays the prevalence of individuals living with a disability in the United Kingdom in 2023/24, by impairment type and age group.

Rates of mortality involving cancers, cardiovascular diseases, chronic kidney disease, dementia, diabetes, and respiratory diseases, by Census 2021 variables. Experimental Statistics.

Emergency admissions to hospital of persons with chronic conditions (asthma, diabetes) usually managed in primary care. The purpose of this indicator is to help monitor NHS success in prevention and treatment outside hospital of certain chronic illnesses that are amenable to management in a primary care setting. In 2014, NHS England set a target to reduce total emergency admissions by 3.5%, ‘as a clear indicator of the effectiveness of local health and care services in working better together to support people’s health and independence in the community’. Emergency admissions to hospital can be avoided if local systems are put in place firstly to identify those at risk prior to attendance and target primary care services, and secondly to identify those emergency department attendees better cared for outside of hospital and provide a safe route into more appropriate community care. The next release date for this indicator is to be confirmed. Legacy unique identifier: P02184

In the period 2019 to 2020, allergies affected approximately 36 percent of women and 30 percent of men in the United Kingdom. Furthermore, just under a fifth of both genders suffered from high blood pressure, while back disorder or defects affected 16.5 percent and 13.9 percent of women and men respectively.

IntroductionThe demographic shift leads to a tremendous increase in age-related diseases, which are often chronic. Therefore, a focus of chronic disease management should be set on the maintenance or even improvement of the patients’ quality of life (QoL). One indicator to objectively measure QoL is the EQ-5D questionnaire, which was validated in a disease- and world region-specific manner. The aim of this study was to conduct a systematic literature review and meta-analysis on the QoL across the most frequent chronic diseases that utilized the EQ-5D and performed a disease-specific meta-analysis for treatment-dependent QoL improvement.Materials and methodsThe most common chronic disease in Germany were identified by their ICD-10 codes, followed by a systematic literature review of these ICD-10 codes and the EQ-5D index values. Finally, out of 10,016 independently -screened studies by two persons, 538 studies were included in the systematic review and 216 studies in the meta-analysis, respectively.ResultsWe found significant medium to large effect sizes of treatment effects, i.e., effect size >0.5, in musculoskeletal conditions with the exception of fractures, for chronic depression and for stroke. The effect size did not differ significantly from zero for breast and lung cancer and were significantly negative for fractures.ConclusionOur analysis showed a large variation between baseline and post-treatment scores on the EQ-5D health index, depending on the health condition. We found large gains in health-related quality of life mainly for interventions for musculoskeletal disease.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020150936, PROSPERO identifier CRD42020150936.

BackgroundAnkylosing spondylitis (AS) is a chronic inflammatory arthritis which typically begins in early adulthood and impacts on healthcare resource utilisation and the ability to work. Previous studies examining the cost of AS have relied on patient-reported questionnaires based on recall. This study uses a combination of patient-reported and linked-routine data to examine the cost of AS in Wales, UK.MethodsParticipants in an existing AS cohort study (n = 570) completed questionnaires regarding work status, out-of-pocket expenses, visits to health professionals and disease severity. Participants gave consent for their data to be linked to routine primary and secondary care clinical datasets. Health resource costs were calculated using a bottom-up micro-costing approach. Human capital costs methods were used to estimate work productivity loss costs, particularly relating to work and early retirement. Regression analyses were used to account for age, gender, disease activity.ResultsThe total cost of AS in the UK is estimated at £19016 per patient per year, calculated to include GP attendance, administration costs and hospital costs derived from routine data records, plus patient-reported non-NHS costs, out-of-pocket AS-related expenses, early retirement, absenteeism, presenteeism and unpaid assistance costs. The majority of the cost (>80%) was as a result of work-related costs.ConclusionThe major cost of AS is as a result of loss of working hours, early retirement and unpaid carer’s time. Therefore, much of AS costs are hidden and not easy to quantify. Functional impairment is the main factor associated with increased cost of AS. Interventions which keep people in work to retirement age and reduce functional impairment would have the greatest impact on reducing costs of AS. The combination of patient-reported and linked routine data significantly enhanced the health economic analysis and this methodology that can be applied to other chronic conditions.

The Health Survey for England series was designed to monitor trends in the nation's health; estimating the proportion of people in England who have specified health conditions, and the prevalence of risk factors and behaviours associated with these conditions. The surveys provide regular information that cannot be obtained from other sources. The surveys have been carried out since 1994 by the Joint Health Surveys Unit of NatCen Social Research and the Research Department of Epidemiology and Public Health at UCL. Each survey in the series includes core questions, e.g. about alcohol and smoking, and measurements (such as blood pressure, height and weight, and analysis of blood and saliva samples), and modules of questions on topics that vary from year to year. The trend tables show data for available years between 1993 and 2016 for adults (defined as age 16 and over) and for children. The survey samples cover the population living in private households in England. In 2016 the sample contained 8,011 adults and 2,056 children and 5,049 adults and 1,117 children had a nurse visit. We would very much like your feedback about whether some proposed changes to the publications would be helpful and if the publications meet your needs. This will help us shape the design of future publications to ensure they remain informative and useful. Please answer our reader feedback survey on Citizen Space which is open until 18 June 2018.

This dataset forms part of the OPTIMising therapies, discovering therapeutic targets and AI-assisted clinical management for patients Living with complex multimorbidity (OPTIMAL) NIHR funded programme.

The dataset includes >40,000 adult patients with multimorbidity who were acutely admitted to hospital and had an inpatient stay. Longitudinal data includes serial physiology readings, frailty scores, blood results, medications, comorbidities, drug allergies, treatments, procedures and mortality outcomes up to a year post discharge.

Geography: The West Midlands (WM) has a population of 6 million & includes a diverse ethnic & socio-economic mix. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & > 120 ITU bed capacity. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.

Data set availability: Data access is available via the PIONEER Hub for projects which will benefit the public or patients. This can be by developing a new understanding of disease, by providing insights into how to improve care, or by developing new models, tools, treatments, or care processes. Data access can be provided to NHS, academic, commercial, policy and third sector organisations. Applications from SMEs are welcome. There is a single data access process, with public oversight provided by our public review committee, the Data Trust Committee. Contact pioneer@uhb.nhs.uk or visit www.pioneerdatahub.co.uk for more details.

All data uses should name both PIONEER and the NIHR Optimal programme in data outputs. This will be specified in the Data Licensing Agreement.

Available supplementary data: Matched controls; ambulance and community data. Unstructured data (images). We can provide the dataset in OMOP and other common data models and can build synthetic data to meet bespoke requirements.

Available supplementary support: Analytics, model build, validation & refinement; A.I. support. Data partner support for ETL (extract, transform & load) processes. Bespoke and “off the shelf” Trusted Research Environment (TRE) build and run. Consultancy with clinical, patient & end-user and purchaser access/ support. Support for regulatory requirements. Cohort discovery. Data-driven trials and “fast screen” services to assess population size.

This report presents the latest figures on male and female health expectancy, at birth and at age 65, for the UK and its four constituent countries. While life expectancy (LE) provides an estimate of average expected life-span, healthy life expectancy (HLE) divides total LE into years spent in good or ‘not good’ health. Disability-free life expectancy (DFLE) divides LE into years lived with and without a chronic illness or disability. These figures are three-year averages. LE is taken from the UK national interim life tables published annually by ONS, and the measures of health and chronic illness from the General Household Survey (GHS) in Great Britain and the Continuous Household Survey (CHS) in Northern Ireland. Source agency: Office for National Statistics Designation: National Statistics Language: English Alternative title: National Health Expectancies

Forecast: Chronic Liver Diseases and Cirrhosis Mortality in the UK 2024 - 2028 Discover more data with ReportLinker!

Forecast: Chronic Obstructive Pulmonary Diseases Mortality in the UK 2024 - 2028 Discover more data with ReportLinker!

We asked UK consumers about "Prevalence of health conditions" and found that "Mental health conditions (e.g., burnout, depression, anxiety)" takes the top spot, while "Physical disabilities (e.g., cerebral palsy, spinal cord injury, limb loss)" is at the other end of the ranking.These results are based on a representative online survey conducted in 2024 among 4,026 consumers in the UK.

In 2019, cancers and cardiovascular diseases had the largest impact in the UK with approximately 3.75 and 2.92 million DALYs respectively. These diseases are identical to diseases with the highest burden in the European Union. Many cancer instances are caused by environmental factors such as unprotected sun exposure, smoking, a sedentary lifestyle, alcohol use, and being overweight.

Chronic kidney disease (CKD) affects up to 15% of the adult population and is strongly associated with other non-communicable chronic diseases including diabetes. However, there is limited information on a population basis of the relationship between CKD and health-related quality of life (HRQoL) and the consequent economic cost. We investigated this relationship in a representative sample in England using the 2010 Health Survey for England. Multivariable Tobit models were used to examine the relationship between HRQoL and CKD severity. HRQoL was converted to quality adjusted life year (QALY) measures by combining decrements in quality of life with reductions in life expectancy associated with increased disease severity. QALYs were adjusted for discounting and monetised using the UK threshold for reimbursement of £30,000. The QALYs were then used in conjunction with forecasted prevalence to estimate the HRQoL burden associated with CKD among individuals with diabetes up to 2025. Individuals with more severe CKD had lower HRQoL compared to those with better kidney function. Compared to those with normal/low normal kidney function and stage 1 CKD, those with stage 2, stage 3 with albuminuria and stage 4/5 CKD experienced a decrement of 0.11, 0.18 and 0.28 in their utility index, respectively. Applying the UK reimbursement threshold for a QALY, the monetised lifetime burden of reduced HRQoL due to stage 2, stage 3 with albuminuria and stage 4/5 CKD were £103,734; £83,399; £125,335 in males and £143,582; £70,288; £203,804 in females, respectively. Utilizing the predicted prevalence of CKD among individuals with diabetes mellitus, the economic burden of CKD per million of individuals with diabetes is forecasted at approximately £11.4 billion in 2025. In conclusion, CKD has a strong adverse impact on HRQoL in multiple domains. The estimated economic burden of CKD among individuals with diabetes mellitus in the UK is projected to rise markedly over time.

Dataset population: Persons

General health

General health is a self-assessment of a person's general state of health. People were asked to assess whether their health was very good, good, fair, bad or very bad.

Type of long-term condition

People with more than one condition are counted separately for each condition but only once in the 'All people'/'All people in households' and 'One or more conditions' categories.

1. A communication difficulty means a difficulty with speaking or making yourself understood.
2. A mobility or dexterity difficulty means a condition that substantially limits one or more basic physical activities such as walking, climbing stairs, lifting or carrying.
3. An emotional, psychological or mental health condition includes conditions such as depression or schizophrenia.
4. Shortness of breath or difficulty breathing includes conditions such as asthma.
5. A chronic illness includes illnesses such as cancer, HIV, diabetes, heart disease or epilepsy.

A long-term condition refers to a condition which has lasted, or is expected to last, at least 12 months.